Seeking Alpha

More on Watson Pharma (WPI +2.1%) Q1: Net income +21% to $54.8M, with earnings boosted by...

More on Watson Pharma (WPI +2.1%) Q1: Net income +21% to $54.8M, with earnings boosted by Watson's generic versions of the Lipitor cholesterol drug and Lovenox blood thinner, and a rise in international sales. 2012 guidance: adjusted EPS $5.55-$5.80 and revenue $5.5B vs. consensus of $5.80 and $5.5B.

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs